
- Mithramycin A
10058-F4C-Myc-Max dimerization inhibitor |
Sample solution is provided at 25 µL, 10mM.
































Quality Control & MSDS
- View current batch:
- Purity = 98.03%
- COA (Certificate Of Analysis)
- HPLC
- MS (Mass Spectrometry)(Retest)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure

Description | 10058-F4 is a small-molecule and cell-permeable inhibitor of c-Myc-Max dimerization. | |||||
Targets | c-Myc-Max dimerization | |||||
IC50 |
Cell experiment [1]: | |
Cell lines | HL-60, U937 and NB-4 cells |
Preparation method | The solubility of this compound in DMSO is > 12.5 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
Reacting condition | 0, 30, 60, 100 and 150 μM; 72 hrs |
Applications | All AML cell lines (HL-60, U937 and NB-4) were sensitive to 10058-F4 in a dose-dependent manner. At the dose of 100 μM, 10058-F4 significantly induced apoptosis of AML cell after the 72-hr treatment. In addition, 10058-F4 decreased levels of c-Myc proteins in all AML cell lines. |
Animal experiment [2]: | |
Animal models | SCID mice bearing DU145 or PC-3 human prostate cancer xenografts |
Dosage form | 20 or 30 mg/kg; i.v.; q.d., 5 days per week, for 2 weeks |
Applications | In mice bearing PC-3 xenografts, intravenous treatment with 20 or 30 mg/kg 10058-F4 resulted in the maximum mean %TC values of 72.3 and 72.9%, respectively. Similarly, in mice bearing DU145 xenografts, 30 mg/kg 10058-F4 resulted in a maximum mean %TC value of 85%. 10058-F4 showed lack of effect in both models. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Huang MJ, Cheng YC, Liu CR, Lin SF, Liu H. E. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Experimental Hematology. 2006; 34: 1480–1489. [2]. Guo J, Parise RA, Joseph E, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25. |

10058-F4 Dilution Calculator
calculate

10058-F4 Molarity Calculator
calculate
Cas No. | 403811-55-2 | SDF | Download SDF |
Synonyms | N/A | ||
Chemical Name | (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one | ||
Canonical SMILES | CCC1=CC=C(C=C1)C=C2C(=O)NC(=S)S2 | ||
Formula | C12H11NOS2 | M.Wt | 249.35 |
Solubility | ≥24.9mg/mL in DMSO | Storage | Store at -20°C |
Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
10058-F4 is a novel small-molecule inhibitor of c-Myc. 10058-F4 prevented the binding of c-Myc/Max dimers to its DNA targets, inhibited leukemic proliferation, and induced apoptosis through mitochondrial pathway, such as downregulation of Bcl-2, upregulation of Bax and release of cytoplasmic cytochrome C. [1]
10058-F4 blocks the C-MYC/Max heterodimerization which is required for c-Myc activity as a transcription factor. 10058-F4 efficiently inhibits the induction of PGC-1β mRNA by both HRG and IGF-1 and also abolishes the induction of PGC-1β protein levels by HRG and IGF-1, confirming that the induction of PGC-1b protein by these growth factors is a transcriptional event requiring C-MYC activity.[2] 10058-F4 acts not only to block c-Myc function through the mechanism of c-Myc/Max heterodimer dissociation, but it also resulted in decreased c-Myc mRNA levels (65%, n = 3) in lymphoma cells.[3]
References:[1] Huang MJ, Cheng YC, Liu CR, Lin SF, Liu H. E. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Experimental Hematology. 2006; 34: 1480–1489.[2] Ching-yi Chang, Dmitri Kazmin, Jeff S. Jasper, Rebecca Kunder, William J. Zuercher, Donald P. McDonnell. The Metabolic Regulator ERRα, a Downstream Target of HER2/IGF-1R, as a Therapeutic Target in Breast Cancer. Cancer Cell. 18 October 2011. 20(4): 500-510.[3] Ilsa Gomez-Curet, R. Serene Perkins, Ryan Bennett, Katherine L. Feidler, Stephen P. Dunn, Leslie J. Krueger. c-Myc inhibition negatively impacts lymphoma growth. Journal of Pediatric Surgery. January 2006. 41(1): 207-211.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
纽约大学的研究团队在CRISPR-Cas9的基础上开发了一个定向检测基因组区域的活体成像系统。该系统能够精确观测基因组位点和细胞核结构,揭示细胞核改变在基因表达调控和其他细胞过程中的重要作用。
CRISPR-Cas9原本是细菌在漫长的进化史中演化出的重要防御机制。规律成簇的间隔短回文重复CRISPR与内切酶Cas9的组合,可以在sgRNA的指引下,靶标并切割入侵者的遗传物质。2012年研究者们利用这一特点,将CRISPR系统发展成了强大的基因组编辑工具。现在CRISPR-Cas9基因组编辑系统的应用延伸到了基因敲除、删除、染色体重排、RNA编辑、全基因组筛选等众多领域。
研究人员用病毒RNA和sgRNA生成了嵌合转录本。这种转录本与缺乏剪切活性的Cas9共表达,可以把荧光标记的病毒RNA结合蛋白招募到基因组指定位点。为了证实CRISPR成像技术的效率和灵活性,研究人员同时标记了小鼠染色体12的两种卫星序列,以及不同的基因组位点。他们在文章中指出,这是一种快速、稳定的低背景成像技术,可以用来追踪染色质互作动态和验证表观遗传学过程。
为了更好的研究非编码RNA,哈佛大学的科学家们以CRISPR为基础打造出了一个定向的RNA定位法——CRISPR-Display(CRISP-Disp)。他们利用失去催化活性的dCas9,将整合在sgRNA中的大片段RNA带到特定DNA位点。文章通讯作者是RNA领域的著名青年科学家JohnRinn博士,他曾被评为2009年美国国内撼动科学界的青年英才。
在CRISPR系统的基础上使用sgRNA文库进行遗传筛选,是鉴定基因调控子的一种有效方法。研究者们可以通过CRISPR筛选在基因组非编码区域中寻找功能性元件。不过这样的应用需要高度覆盖又简单实用的自定义sgRNA文库。耶鲁大学医学院的研究人员开发了一个名为MolecularChipper的新技术。该技术能够针对指定基因组区域生成密集覆盖的sgRNA文库。
酿脓链球菌的Cas9现在已经被广泛用于基因组编辑。那么,对Cas9进行基因工程改造将面临哪些限制呢?加州大学伯克利分校的研究团队通过随机插入突变对Cas9结构进行了全面分析,鉴定了这种蛋白的基因改造热点。这些位点可以耐受PDZ结构域的插入,不影响Cas9的结合和剪切功能。
光系统设计难各种光系统都各自特点所像质优化重点全致 没像数或者物理领域种著名课题 希望能帮
请问成像系统工作站请问那家的产品做得比较好以及专业一些呢?
图1 光声成像工程 (a)光声信号激发与探测;(b)光声成像实现过程示意图
光声成像过程可以分为三个部分:信号的产生、信号的接收和信号处理及图像重建(见图1)。由于脉冲激光器具有光声转换效率高的优点,因此通常被作为光声成像研究中产生信号的激励源。脉冲激光器发出的激光束照射在待研究组织样品上,由于组织样品的吸收效应,在样品内部形成了与组织光学参数相关的能量沉积分布。由于激光脉宽很窄(ns)吸收的能量不能在短时间内释放,导致瞬间温度变化,从而通过热弹机制转化为热膨胀。周期性热流使周围的介质热胀冷缩而激发超声波,由于这种超声波信号的特殊产生机理,为了区别于其它的超声信号,通常称为光声信号。利用超声探测器接收光声信号并对采集到的信号进行适当地处理和采用相应的图像重建算法,就能够得到样品内部光能量沉积的分布。当保证入射光的均匀性的前提下,光声重建图像与吸收分布具有一一对应的关系。向左转|向右转
显微镜是OlympusDP71,弄比例尺的时候出来个“衸”,这是什么鬼啊?如何换算成微米?测量的那个选项我选的是10微米,也只有那个选项可以点。然后倍数选择200,然后他就出来这个200衸,选100倍数是500衸,400倍是200也衸,但长度是200的两倍,**各位大神帮帮忙,要怎样才能换成微米?另外1衸是多少微米?
总局关于发布医用磁共振成像系统临床评价等4项医疗器械注册技术审查指导原则的通告(2017年第6号)
2017年01月16日发布http://www.sfda.gov.cn/WS01/CL0087/168596.html
为加强医疗器械产品注册工作的监督和指导,进一步提高注册审查质量,国家食品药品监督管理总局组织制定了《医用磁共振成像系统临床评价技术审查指导原则》《口腔颌面锥形束计算机体层摄影设备注册技术审查指导原则》《体外除颤产品注册技术审查指导原则》《光固化机注册技术审查指导原则》(见附件),现予发布。
特此通告。
附件:1.医用磁共振成像系统临床评价技术审查指导原则
2.口腔颌面锥形束计算机体层摄影设备注册技术审查指导原则
3.体外除颤产品注册技术审查指导原则
4.光固化机注册技术审查指导原则
食品药品监管总局
2017年1月10日
2017年第6号通告附件1.docx
2017年第6号通告附件2.docx
2017年第6号通告附件3.doc
2017年第6号通告附件4.docx
实验室新组建,想咨询一下Camag薄层色谱成像系统的价格及一套显微成像的设备清单与价格。显微成像主要用于中药材的显微鉴别

